Lycia Proposes $16 To $18 IPO Range As Cash Falls To $138.2 Million

The biotech's amended S-1 offers 14,700,000 shares and shows estimated cash below its June level.

Share
Lycia Proposes $16 To $18 IPO Range As Cash Falls To $138.2 Million

Lycia Therapeutics proposed a $16.00 to $18.00 per share range for 14,700,000 shares in an amended S-1 filed Tuesday. The IPO has not priced; the company has applied to list on the Nasdaq Global Select Market under the symbol "LYCA."

What the amended filing says

The underwriters hold a 30-day option to buy up to 2,205,000 more shares. At the $17.00 midpoint, the company estimates net proceeds of about $227.8 million, or about $262.7 million if the option is exercised in full.

The offering is contingent on Nasdaq approving the listing. The cover leaves the final price and totals blank.

The filing also carries a preliminary, unaudited estimate of about $138.2 million in cash, cash equivalents and marketable securities as of September 30, 2026. It was $148.1 million at June 30, 2026. The auditor, KPMG, has not reviewed the estimate.

A 1-for-4.5087 reverse stock split took effect October 19, 2026. After the offering, 52,094,559 shares would be outstanding, or 54,299,559 if the option is exercised in full. That count assumes the preferred stock converts into 34,141,408 common shares when the offering completes.

What it changes for the company

Management says the proceeds plus existing cash should fund operations into the second half of 2029. It also warns that it will need substantial additional capital even if the offering succeeds.

The company reports no product revenue. Collaboration revenue was $6.741 million in 2025 and $14.936 million in 2024, and nothing in the first six months of 2026. Net loss was $36.5 million for 2025 and $19.2 million for the six months ended June 30, 2026.

The lead program, LCA-0061, targets IgE, a driver of allergic disease. In the first cohort given a single 70 mg dose, the filing reports a mean maximum IgE reduction of 96% from baseline, with no safety signals observed. The company expects additional data in healthy participants with elevated IgE and in food allergy patients in 2027. It also expects initial data in 2027 for LCA-0321, its Graves' disease program.

What to watch

A later filing must set the final price and share terms, and Nasdaq must approve the listing. Each $1.00 change in the price from the $17.00 midpoint would move pro forma cash by about $13.7 million, the filing says.

The 2027 readouts for LCA-0061 in food allergy patients are the next data the company has said to expect.

Sources